AsclepiX Therapeutics is dedicated to revolutionizing the treatment of ocular diseases through innovative therapies that leverage the body's natural mechanisms of vascular homeostasis. The company employs advanced computational biology techniques to identify and develop peptide-based clinical candidates that regulate vascular stability. Their lead candidate, AXT107, specifically targets the vascular endothelial growth factor receptor 2 (VEGFR2) and activates the Tie2 receptor, both of which are critical pathways in managing retinal vascular diseases. AXT107 is formulated as a microparticulate suspension for intraocular injection, designed to enhance treatment durability and reduce the frequency of injections required compared to existing therapies. This approach aims to improve patient outcomes in conditions such as wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO).

The technology behind AsclepiX Therapeutics is rooted in the principle of homeostasis, which is essential for maintaining health. By utilizing computational methods to discover novel anti-angiogenic peptides within the human proteome, the company has identified multiple peptide families that can effectively regulate neovascularization—a process often disrupted in various ocular diseases. These peptides are derived from structural proteins and other biological molecules that play a role in maintaining vascular stability. Through rigorous in vitro and in vivo testing, AsclepiX has confirmed the efficacy of these peptides in inhibiting abnormal blood vessel growth and inflammation, thereby addressing significant unmet medical needs in the field of ophthalmology.

United States

AsclepiX Therapeutics is focused on transforming the treatment of ocular diseases through the rapid clinical development of groundbreaking therapies aimed at empowering patients and their families around the world with the freedom to live their best lives.

Using pioneering computational biology methods, we have identified multiple families of peptides that are potent regulators of vascular homeostasis. Our clinical candidates are derived from these peptides and work through naturally existing, highly evolved, and self-regulating mechanisms of homeostasis that maintain our health and well-being.

AsclepiX Therapeutics

Company Details